Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» JPMHC 2019
JPMHC 2019
J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis
Fierce Pharma
Wed, 01/9/19 - 12:56 pm
JNJ
JPMHC 2019
immunology
psoriasis
Tremfya
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
BioSpace
Wed, 01/9/19 - 09:40 am
JPMHC 2019
M&A
Eli Lilly
Loxo Oncology
SAGE Therapeutics
Sanofi
Regeneron
Bristol-Myers Squibb
Celgene
Novartis
Gilead Sciences
Here's Why Nektar Therapeutics Surged Today
Motley Fool
Tue, 01/8/19 - 07:12 pm
Nektar Therapeutics
JPMHC 2019
NKTR-214
JPM: Why hasn't Merck been making deals? It's not for lack of trying, CEO says
Fierce Pharma
Tue, 01/8/19 - 10:37 am
Merck
Pharma CEOs
Ken Frazier
M&A
JPMHC 2019
7 Things to Expect for Gilead Sciences in 2019
Motley Fool
Tue, 01/8/19 - 09:12 am
Gilead Sciences
JPMHC 2019
HIV
hepatitis C
M&A
Daniel O'Day
JPM: Years into troubled launch, vaccine head says Sanofi's learned some Dengvaxia lessons
Fierce Pharma
Tue, 01/8/19 - 11:24 am
Sanofi
Dengvaxia
vaccines
dengue
JPMHC 2019
3 Things Bristol-Myers Squibb Understands About Celgene That the Market Hasn't
Motley Fool
Tue, 01/8/19 - 12:43 am
Celgene
Bristol-Myers Squibb
M&A
JPMHC 2019
3 Things Pfizer's New CEO Just Said That Investors Will be Glad to Hear
Motley Fool
Tue, 01/8/19 - 12:40 am
Pfizer
Albert Bourla
Pharma CEOs
JPMHC 2019
Novartis building out cell and gene therapy platform that'll lead the pack, CEO promises
Fierce Pharma
Tue, 01/8/19 - 12:38 am
Novartis
Pharma CEOs
CAR-T
Kymriah
Vas Narasimhan
JPMHC 2019
A New Day, a New Vant. Roivant Launches Alyvant Ahead of J.P. Morgan 2019
BioSpace
Mon, 01/7/19 - 12:24 pm
Vivek Ramaswamy
Roivant
Alyvant
JPMHC 2019
The Week Ahead In Biotech: Conferences, Clinical Trials
Yahoo/Benzinga
Sun, 01/6/19 - 01:55 pm
JPMHC 2019
Axsome Therapeutics
Miragen Therapeutics
Aptorum Group
IPOs
After Bristol-Myers Squibb Buys Celgene What's Next? JP Morgan's Conference Will Answer That
Forbes
Sat, 01/5/19 - 03:04 pm
Celgene
Bristol-Myers Squibb
M&A
JPMHC 2019
A year after ‘the Michaels,’ more women will take the JPM stage — but 90 percent of presenters are still male
Stat
Sat, 01/5/19 - 01:43 pm
JPMHC 2019
gender diversity
Pages
« first
‹ previous
1
2